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Abstract
Introduction: Restriction factors (RFs) suppress HIV-1 in cell lines and primary cell models. Hence, RFs might be attractive
targets for novel antiviral strategies, but their importance for virus control in vivo is controversial.
Methods: We profiled the expression of RFs in primary blood-derived mononuclear cells (PBMC) from therapy-naïve HIV-1
patients and quantified infection.
Results: Overall, there was no correlation between individual RF expression and HIV-1 status in total PBMC. However, we
identified a T cell population with low levels of intracellular CD2 and reduced expression of SAMHD1, p21 and SerinC5. CD2low T
cells with reduced RF expression were markedly positive for HIV-1 p24. In contrast, CD2+ T cells were less infected and expressed
higher levels of RFs. CD2low T cell infection correlated with viral loads and was associated with HIV-1 disease progression.
Conclusions: In untreated therapy naïve chronic HIV-1 patients, RF expression in T cells is associated with CD2 expression and
seems to influence viral loads. Our study suggests that RFs help to control HIV-1 infection in certain T cells in vivo and
supports the potential for RFs as promising targets for therapeutic intervention.
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Introduction
Various cellular gene products interfere with virus replica-
tion. These cellular factors are termed virus restriction
factors (RFs) [1]. The function of RFs in cellular processes
are in many cases unclear and it is tempting to speculate
that they are in first-order components of the so-called host
intrinsic immunity for frontline protection against virus
infections [1].
In general, RFs are capable of significantly decreasing
production of infectious virus and many viruses developed
strategies to antagonize the antiviral activity of RFs.
Moreover, expression of many RFs is inducible by interfer-
ons and RFs often show signatures of rapid evolution by
positive selection of conserved amino acid residues [1,2]. In
the last years, a series of RFs attacking HIV at various stages
of the viral replication cycle were identified [2,3]. Targeting
the activity of RFs in the context of antiviral therapy or
vaccination seems an attractive approach. However, up to
now, clear evidence for the in vivo importance of RFs for
HIV-1 control is largely missing, controversial [4–7] and/or
is derived from non-human in vivo models [8–13].
We initiated this study to analyse the importance of RFs
in antiretroviral treatment naïve HIV-1 patients that control
the infection or, alternatively, progressed to high viral loads.
In patient-isolated peripheral blood mononuclear cells
(PBMC), we profiled transcription and protein expression
of four RFs that inhibit HIV-1 at different stages of viral
replication. RFs investigated include the sterile alpha motif
(SAM) and histidine-aspartate (HD) domain-containing pro-
tein 1 (SAMHD1), which inhibits reverse transcription of the
viral genome by lowering the dNTP pool [3,14,15]. The
cyclin-dependent kinase (CDK) inhibitor p21 (also termed
Waf1/Cip1) interferes with HIV-1 integration and restricts
early replication in CD4+ T cells, macrophages and hema-
topoietic cell lineages [16–18]. The Rev interacting protein
(RISP) restricts HIV-1 production in astrocytes by inhibition
of HIV-1 Rev [19]. Tetherin inhibits HIV-1 release from sites
of viral budding and assembly at the plasma membrane
[20,21]. Furthermore, we analysed a smaller subset of
patients for the recently identified suppressor of HIV-1
infectivity SerinC5 [22,23]. We observed no general differ-
ences in RF expression in total PBMC between patients with
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disease progression or patients controlling the infection.
However, we identified a CD4+ T cell population with low
levels of intracellular CD2 and high HIV-1 infection rates in
comparison to CD4+ CD2+ cells. Strikingly, CD4+ CD2low T
cells expressed reduced levels of RFs SAMHD1 and p21 and
HIV-1 p24 staining in these cells was associated with viral
loads. Overall, our results indicate that RF expression could
influence infection rates in HIV-1 patients and could hence
be determinants of HIV-1 control in vivo.
Methods
Ethic approval and consent to participate
44 individuals participated in the study after signing
informed consent. The study was approved by the IRB of
the Ludwig-Maximilians-Universität, Munich, Germany
(Project No. 274-03). All experiments were performed in
compliance with relevant laws and institutional guidelines
and in accordance with the ethical standards of the
Declaration of Helsinki.
Study subjects
All study subjects were ART naïve and divided into the
following groups [1]: HIV-1 viraemic controllers, defined
by CD4 counts >400 cells/µl and viral loads <5000 copies/
ml and [2] HIV-1 progressors with CD4 counts <400 cells/µl
and viral loads >10,000 copies/ml (details see Table 1).
From each patient, we had one aliquot of PBMC available
that were isolated from approximately 10 ml EDTA blood by
Ficoll density-gradient centrifugation and stored in liquid
nitrogen until further usage. We also isolated PBMC from
three individuals on antiretroviral therapy with no detect-
able viral loads and high and stable CD4+ T cell counts. For
analyses of healthy donor RF expression in PBMC and ex
vivo infection experiments, we isolated PBMC from buffy
coat as described [24].
RNA isolation and qRT-PCR
RNA was isolated from PBMC using the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s protocol. RF
mRNA levels of Tetherin, SAMHD1, p21 and RISP were
determined by One-Step qRT-PCR Kit (Roche) according to
Table 1. Characteristics of HIV-1-positive individuals included in this study.
Controllers Progressors
ID CD4 T cells Viral load Gender Age ID CD4 T cells Viral load Gender Age
CO 01 765 201 m 53 PR 01 293 181,497 m 38
CO 02 477 498 f 32 PR 02 204 69,915 m 33
CO 03 782 3101 f 43 PR 03 150 <500,000 m 34
CO 04 517 2247 f 51 PR 04 221 151,857 m 34
CO 05 473 2835 m 58 PR 05 395 152,867 m 62
CO 06 715 3286 m 43 PR 06 297 11,683 m 53
CO 07 547 103 f 32 PR 07 58 11,805 m 46
CO 08 1578 682 m 39 PR 08 362 49,129 m 35
CO 09 413 3032 m 67 PR 09 372 36,824 m 37
CO 10 653 2567 m 50 PR 10 251 68,277 m 73
CO 11 456 472 m 39 PR 11 277 131,229 m 32
CO 12 655 1739 m 26 PR 12 207 44,023 m 42
CO 13 670 <50 f 48 PR 13 190 43,551 m 48
CO 14 500 3421 m 31 PR 14 326 113,164 m 44
CO 15 586 933 m 54 PR 15 193 43,021 m 56
CO 16 1050 1978 f 30 PR 16 246 56,407 m 33
CO 17 1532 <50 m 62 PR 17 196 32,523 m 43
CO 18 833 2142 f 73 PR 18 227 58,272 f 60
CO 19 807 865 m 47 PR 19 341 62,625 m 39
CO 20 598 2180 f 25 PR 20 268 66,885 f 29
CO 21 529 386 m 24 PR 21 290 20,576 m 30
CO 22 785 3739 f 34 PR 22 205 18,000 m 34
CD4 T cell counts are measured as the absolute number of peripheral T cells per μl blood. Similarly, viral load is the absolute number of
proviral copies per ml serum. Controllers are defined by viral loads less than 5000 copies/ml and CD4 T cell counts higher than 400 cells/
μl. In contrast, progressors have viral loads higher than 10,000 copies/ml and CD4 T cell counts less than 400 cells/μl. Controllers have a
stable course of infection for at least six years. All patients are antiretroviral treatment naïve or have not received antiretroviral therapy
for at least 2 years.
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the manufacturer’s protocol using specific primer pairs for
amplification of Tetherin (forward primer: 5
´-CTGCAACCACACTGTGATG-3´; reverse primer: 5
´-ACGCGTCCTGAAGCTTATG-3´) [25], SAMHD1 (forward pri-
mer: 5´-TCGTCCGAATCATTGATACACC-3´; reverse primer: 5
´-CCAGTGCGTGAACTAGACATCC-3´) [26], p21 (forward pri-
mer: 5´-GGAAGACCATGTGGACCTGT-3´; reverse primer: 5
´-GGCGTTTGGAGTGGTAGAAA-3´) [27], RISP (forward pri-
mer: 5´GGAAGCAATTAAACCCTCTCA-3´; reverse primer: 5
´-TTTGGTTTTACAGTTAAGTCAGCAA-3´) and RNA polymerase
II (forward primer: 5´GCACCACGTCCAATGACAT-3; reverse
primer: 5´-GTGCGGCTGCTTCCATAA-3´) [28]. Quantitative
RT-PCR was performed as described [29].
Flow cytometry analysis of RF expression
We aimed to measure intracellular CD2, HIV-1 p24 and the
expression of a RF in one staining step. Hence, for the
intracellular stainings, PBMC were fixed with 2% PFA for
20 min at 4°C and permeabilized with 1% Saponin for
10 min at RT. Afterwards, cells were separated into different
aliquots and intracellularly stained with one of the following
antibodies: either human Tetherin-Alexa Fluor 647
(BioLegend), p21 (Proteintech), SAMHD1 (Proteintech), RISP
[19] or SerinC5 (Abcam). Then cells were stained with the
corresponding secondary antibodies either anti-mouse, anti-
rat or anti-rabbit Alexa Fluor 633 (Molecular Probes,
Invitrogen). In addition, we used anti-p24-FITC (Beckman
Coulter Clone KC57) and anti-CD2-Pacific blue (BioLegend).
For the surface staining we used either anti-CD3-APC
(Invitrogen), anti-CD4-APC (Invitrogen), anti-CD62L-APC
(BioLegend) or Tetherin-Alexa Fluor 647 (BioLegend).
Then, cells were intracellularly stained for p24 and CD2 as
described above. We measured with a FACS CANTOII with
similar PMT voltage settings throughout the study and
analysed the data with the FACSDiva software (BD
Biosciences) or Flowlogic (Miltenyi/Inivai).
Ex vivo HIV-1 infection of PBMC
PBMC isolation from buffy coat, stimulation, production of
HIV-1 NL4-3 virus stock and quantification of p24 was done
as described [24]. 48 h post infection cells were harvested
and stained for surface CD3 (anti-CD3-VioBlue, Miltenyi)
and intracellular HIV-1 with anti-p24-FITC as described
above. CD3 expression levels and HIV-1 infection was ana-
lysed by flow cytometry.
Statistical analyses
We used GraphPad Prism 6.0 for all statistical calculations.
Data sets were first assessed for normal distribution with
the D’Agostino-Pearson omnibus test. Then, depending on
normal- or non-normal data distribution we tested for sig-
nificance with the appropriate test as indicated in the figure
legend of each data set.
Results
Profiling of RF transcript levels in PBMC from HIV-1
controllers and progressors
The expression of RFs could be an important determinant of
HIV-1 disease progression in patients. We therefore measured
the expression levels of the RFs SAMHD1, p21, RISP and
Tetherin atmRNA level in a cohort of therapy naïve HIV-positive
individuals.
The baseline characteristics of HIV-1 patients analysed in
this study are outlined in Table 1. CD4+ T cell counts inversely
correlated with viral loads (Spearman r = −0.7439; p < 0.0001)
whereas patient age was neither associated with viral loads
nor CD4+ T cell counts.
Total RNA was isolated from patients’ PBMC and RF expres-
sion was determined in 15 viraemic controllers and 15 progres-
sors by qRT-PCR. The RNA expression pattern of the various RFs
was divergent, however, in a similar range as the RNA levels in
PBMC directly isolated from buffy coats of healthy individuals
(Figure 1).
Figure 1. Quantification of RF mRNA levels in PBMC of HIV-1-positive controllers versus progressors. RF mRNA levels of SAMHD1, p21,
RISP and Tetherin in HIV-1-positive controllers (CO) and progressors (PR) of 15 donors were determined by One-Step qRT-PCR Kit (Roche)
using specific primer pairs (see Material and Methods). The mRNA expression was plotted relative to the mRNA levels of the RNA
polymerase II (RPII). Each data point represents the specific mRNA expression of the indicated RF in one patient. For comparison to RF
mRNA levels in uninfected individuals, we also profiled PBMC from three healthy donors (HD). Mean values of RF mRNA expression of
controllers and progressors were analysed for statistical differences using an unpaired two-tailed Mann–Whitney test assuming non-
Gaussian distribution (Graph Pad Prism 6). ns, not significant.
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PBMC mRNA levels of SAMHD1, p21, RISP and Tetherin
did not show any significant differences between HIV-1-
positive individuals controlling the infection or conversely
showing a progressive course of infection. Closer examina-
tion of any potential association between RF mRNA expres-
sion and CD4+ T cell counts or viral load also did not reveal
any significant correlation (data not shown). In conclusion,
mRNA levels of SAMHD1, p21, RISP or Tetherin in PBMC of
HIV-1 patients do not show a specific association with HIV-1
control or viral loads.
Profiling of RF protein expression in PBMC of HIV-1-
positive viraemic controllers and progressors by flow
cytometry
RF levels measured by mRNA transcription might not
necessarily reflect the total abundance of translated pro-
tein. Hence, we quantified RF expression in PBMC of the
HIV-1-positive patients by flow cytometry, allowing to
assess various parameters in one measurement at a sin-
gle cell level. PBMC were analysed for cell surface expres-
sion of CD3 to identify T cells and further CD4 (Figure 2
(a)). In addition, we measured cell surface expression of
Tetherin and CD62L, which was recently shown to be
specifically downregulated in HIV-1-positive T cells [30].
Another aliquot of the PBMC was permeabilized and
stained for intracellular expression of SAMHD1, p21,
RISP and Tetherin (Figure 2(b)). Furthermore, we directly
assessed the proportion of PBMC positive for the HIV-1
antigen p24 (Figure 2(c)) and included CD2 (Figure 2(d)) in
the intracellular stain, as it is a potential marker for latent
HIV-1 infection [31]. Importantly, our rational to measure
intracellular (i.e. total) CD2 was based on the data of
Iglesias-Ussel and colleagues that identified CD2 as a
latency marker by mRNA profiling [31]. As a control, RF
expression levels and p24 infection rates were also mea-
sured in PBMC of healthy donors (HD) and we checked
for p24 levels in PBMC of HIV-1 patients on antiretroviral
therapy (ART) (Figure 2(c)).
Cell surface levels of CD3, CD62L and Tetherin did not
differ between PBMC of viraemic HIV-1 controllers versus
progressors, although CD3 and Tetherin levels were gener-
ally higher in HIV-1-positive individuals, than in healthy
donors (Figure 2(a)). As expected, given that our cohort
definitions are valid [32], CD4 levels of PBMC isolated
from HIV-1-positive patients were reduced and progressing
individuals had lower CD4 levels than viraemic controllers
(Figure 2(a)). The differences in CD4 levels are most likely
not due to active downregulation in the bulk culture of
PBMC but reflect, as expected, the reduced frequency of
CD4+ T cells in HIV-1-positive individuals.
Intracellular expression levels of all RFs tested (SAMHD1,
p21, RISP, Tetherin) did not reveal any differences in total
PBMC potentially associated with HIV-1 control or a pro-
gressing course of infection (Figure 2(b)). RFs seem to be
induced in HIV-1-positive individuals irrespective of their
disease status (Figure 2(b)), which might reflect a generally
increased state of immune activation in HIV-1 patients. The
percentage of PBMC staining positive for HIV-1 p24 varied
strongly between 0.13% and 6.65%, indicating that in some
patients a substantial proportion of PBMC might be produc-
tively infected (Figure 2(c)).
The p24 antibody clone KC57 is widely used for detection
of HIV-1 infection, but was recently also reported to pro-
duce some background signal in PBMC [33]. As control, we
hence infected PBMC from three healthy donors ex vivo
and stained for intracellular p24 (Figure S1). We detected
infection rates between 16% and 36% with low background
staining in mock infected samples in the range of 0.01–
0.03%. Background levels in healthy donor PBMC and HIV-1
patients on ART that were treated exactly as the patient
PBMC (i.e. no cultivation and stimulation) showed indeed
approximately one magnitude higher background p24 stain-
ing in the range of 0.1% (Figure 2(c)). Nevertheless, we
consistently measured higher p24 signals in the untreated
patient PBMC than in our HD and ART controls, altogether
demonstrating specific detection of p24 above background
levels with our staining procedure (Figure 2(c)).
In sum, the percentage of p24+ cells in PBMC did not
differ between HIV-1 viraemic controllers and progressors
(Figure 2(c)) and this was also true for the overall distribu-
tion of the potential HIV-1 latency marker CD2 (Figure 2(d)).
Hence, in agreement with the mRNA profiling, RF expres-
sion levels in total PBMC seem not to be associated with
the course of HIV-1 infection.
Expression of RFs in patient PBMC is associated with CD2
In the context of our data analyses, we noticed apparent
differences in RF expression of CD2+ versus CD2low cells.
One example of a representative SAMHD1 staining is pre-
sented in Figure 3.
From this patient (CO14), 71.3% of PBMC were highly
positive for CD2 (CD2+), whereas the remaining 28.7% of
cells expressed considerably lower amounts of CD2
(defined as CD2low). The CD2+ cells expressed ~2.5-fold
higher levels of SAMHD1 (mean fluorescence intensity
[MFI] = 51,719) than the CD2low PBMC (MFI = 19,367). In
addition, 4.1% of PBMC in the CD2low fraction were HIV-1
p24 positive in comparison to 0.2% of CD2+ cells (see
Figure 3). This prompted us to investigate potential differ-
ences in RF expression between CD2+ and CD2low cells
across all patients included in our cohort (Figure 4).
We observed markedly reduced cell surface levels of CD3
and CD62L in the CD2low fraction of PBMC. Differences in
CD4 were only minor and surface Tetherin levels were
similar between CD2+ and CD2low PBMC from all patients
(Figure 4(a)). In contrast, intracellular RF levels of SAMHD1
and p21 were strongly reduced in the CD2low PBMC sub-
population as compared to its CD2+ counterparts and we
observed the similar albeit less pronounced phenotype for
Tetherin (Figure 4(b)). Notably, the putative Rev inhibiting
factor RISP, an HIV-1 RF that is specifically active in astro-
cytes, was slightly upregulated in CD2low PBMC. In a small
set of patients, we also measured expression of the
recently discovered inhibitor of HIV-1 infectivity SerinC5,
which is counteracted by the viral Nef protein [22,23,34]
and SerinC5 was clearly reduced in the CD2low fraction of
patient PBMC (Figure S2).
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Importantly, CD2low cells do not seem to be more acti-
vated than their CD2+ counterparts, since ex vivo PHA
stimulation of PBMC induces CD2 expression (Figure S3).
Furthermore, three receptors that are usually upregulated
in activated T cells, CD132, CD134 and CD229 [35], were
similarly expressed in CD2+ vs. CD2low cells of patients or
reduced in the CD2low fraction (Figure S4). In summary, we
conclude that the CD2low population of PBMC expresses
Figure 2. Quantification of host cell factors, intracellular p24 as well as CD2 expression in PBMC of HIV-1-positive controllers versus
progressors. (a) PBMC of 44 HIV-1 patients (22 controllers (CO) and 22 progressors (PR)) or six healthy donors (HD) were surface stained
for human CD3, CD4, CD62L and Tetherin with specific antibodies and analysed by flow cytometry as described in detail in the Material
and Methods section. (b) PBMC of 44 HIV-1 patients (22 controllers (CO) and 22 progressors (PR)) or six healthy donors (HD) were fixed,
permeabilized, stained for intracellular SAMHD1, p21, RISP and Tetherin and analysed by flow cytometry. (c) In addition, cells were
stained for intracellular p24 (here, we included three healthy donors and three HIV-1 patients on antiretroviral therapy (ART)) and (d) CD2
in PBMC and CD4+ T cells. Each data point represents the specific flow cytometry measured relative expression of the indicated cellular
factor in one patient. Values were plotted and assessed for statistical significance using the Kruskal–Wallis test with Dunn’s multiple
comparison (Graph Pad Prism 6). MFI, mean fluorescence intensity; ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; ****
p < 0.0001.
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lower levels of HIV-1 RFs, more specifically SAMHD1 and
p21 which are suppressors of HIV-1 reverse transcription
and integration [14,15,17,36,37].
Patient-derived CD2low T cells stain highly positive for the
HIV-1 infection marker p24
Reduced expression of SAMHD1 and p21 in CD2low PBMC of
HIV-1-positive patients could render these cells more per-
missive for infection. In order to test this hypothesis we
analysed the proportion of HIV-1 p24+ cells in the CD2+
versus CD2low fraction of patients’ PBMC (Figure 5(a) and
Figure S5 showing primary FACS plots of the stainings).
Of note, patients’ PBMC expressing low levels of CD2
were infected more efficiently (mean infection rate 1.43%
p24+ cells) than those expressing high amounts of CD2
(mean infection rate 0.59%; Figure 5(a), panel 1).
Inclusion of CD3 or CD4 in our FACS measurements allowed
us to monitor the overall infection not only in PBMC but
also in the CD3+ or CD4+ fraction of cells (Figure 5(a),
panels 2 and 3, see also Figure S5 for representative pri-
mary FACS plots). Indeed, infection rates were higher in the
overall T cell population (CD3+) and most pronounced, as
expected, in the CD4+ cells. Furthermore, the difference in
infection rates between CD2+ and CD2low T cells remained.
On average 1.08% of CD2+ CD3+ cells were HIV-1 p24+,
whereas 5.27% of the CD2low CD3+ cells scored positive for
HIV-1 p24 (Figure 5(a), panel 2). In the CD2+ CD4+ cell
population, 2.24% were p24+ whereas infection rates of
the CD2low CD4+ cells were with 10.33% nearly 5-times
higher (Figure 5(a), panel 3). Hence, the CD4+ CD2low frac-
tion of cells within a patient can be infected to relatively
high levels.
CD2low T cells might get infected due to the low abun-
dance of RFs. We therefore hypothesized that the CD2low T
cell infection rate could be associated with HIV-1 disease
status. To test for this, we first plotted the infection rates of
CD2+ PBMC (Figure 5(b), panel 1), CD2+ CD3+ T cells
(Figure 5(b), panel 2) and CD2+ CD4+ cells (Figure 5(b),
panel 3) of HIV-1 patients controlling the infection or show-
ing a progressive course of infection. As expected, CD2+ T
cell infection did not differ between both groups.
Furthermore, infection rates of CD2low PBMC (Figure 5(c),
panel 1) and CD2low CD3+ T cells (Figure 5(c), panel 2) were
similar. In contrast, CD2l°w CD4+ cells of HIV-1 patients with
a progressive course of infection had higher p24 levels than
CD2low CD4+ cells isolated from controllers (Figure 5(c),
panel 3). More importantly, we measured a direct correla-
tion between p24 levels of the CD2low CD4+ cell fraction
and patients’ viral loads (Figure 6(a)) and a strong trend
(p = 0.0579) towards an inverse correlation with patients'
CD4+ T cell counts.
As control, there was no correlation when we plotted the
clinical parameters against the fraction of infected CD2+
CD4+ cells (Figure 6(b)). We conclude from these data,
that cells with reduced CD2 expression are preferentially
HIV-1-infected in patients and p24 levels of CD2low CD4+ T
cells are associated with HIV-1 viral loads.
Discussion
In vitro RFs suppress HIV-1 replication at various stages.
However, there is sparse and conflicting evidence support-
ing a relevant role of RFs for lentiviral control in vivo
[4,5,7,10–13,38]. It is hence unclear if RFs have the poten-
tial to lead to new therapeutic avenues. HIV-1 has evolved
potent measures to counteract diverse RFs, e.g. Vpu coun-
teracts Tetherin [20,21], Vif inactivates APOBEC3G [39] and
Nef antagonizes SERINC3/C5 [22,23,34]. Furthermore,
viruses rapidly adapt and evade the host’s specific antiviral
immune defence [40]. IFNα induces RFs [1] which serum
levels inversely correlate with T cell counts and are posi-
tively associated with viral loads and high levels of immune
activation predictive for HIV-1 progression [5,6,41].
Therefore, RFs seem not to have a major impact on HIV-1
titres or pathogenesis in vivo.
The largest body of evidence supporting an important
role of RFs for HIV-1 control in vivo stems from studies, in
which HIV-1/HCV co-infected individuals were treated with
IFNα. In one trial enrolling 860 HIV-1/HCV patients that had
not received IFNα treatment before (~80% received ART
against HIV-1), IFNα resulted in decreased CD4+ T cell
numbers and 0.7 log reduced viral loads [42]. In a small
Figure 3. General gating and exemplary dot plot of SAMHD1 staining in CD2+ and CD2low cells in PBMC of one HIV-1-positive individual
(CO14). Exemplary primary FACS staining of PBMC of one patient for intracellular CD2, SAMHD1 and p24. We first gated on living cells
according to FSC and SSC, then we identified CD2+ vs. CD2low cells by CD2-Pacific blue staining. This allowed to specifically measure RF
expression (in the example above SAMHD1 via intracellular Alexa633 stain) and the proportion of HIV-1 p24+ cells (p24-FITC). Indicated
are the percentages of cells positively stained for CD2 or p24 respectively, as well as the mean fluorescence intensity (MFI) of SamHD1.
See Material and Methods for details concerning the staining procedure.
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number (n = 10) of HIV-1/HCV co-infected patients treated
with or without IFNα a slight reduction in cell-associated
viral RNA but no effects on plasma viral load, CD4+ T cells
or other HIV-1 disease markers was observed [43]. In ART-
naïve HIV-1/HCV co-infected patients, IFNα treatment also
leads to a reduction of HIV-1 viral loads and a significant
induction of RFs [41]. Finally, IFNα monotherapy in therapy-
naïve HIV-1 patients had no effects on CD4+ T cell counts
but resulted in an ~0.6 log decrease in viral loads, although
these effects were highly variable, transient and the patient
cohort was small (n = 11) [44]. IFNα induces pleiotropic
effects and its administration could enhance as well as
suppress HIV-1 by various independent mechanisms.
Hence, it is difficult to devise definite conclusions on the
in vivo relevance of RFs for HIV-1 control from the afore-
mentioned studies.
Figure 4. Surface and intracellular host cell factor expression in PBMC of HIV-1-positive individuals in CD2+ versus CD2low cells. (a) PBMC
of HIV-1 patients were surface stained for human CD3, CD4, CD62L and Tetherin as well as intracellular CD2 (see Material and Methods)
and analysed by flow cytometry. (b) PBMC of HIV-1 patients were fixed, permeabilized and stained for intracellular SAMHD1, p21, RISP
and Tetherin as well as CD2 and analysed by flow cytometry. Each data point represents the specific flow cytometry measured relative
expression of the indicated cellular factor in one patient. Values obtained from all measurements were grouped according to the CD2
expression (compare Figure 3) and potential differences were assessed for statistical significance with a two-tailed Wilcoxon matched-
pairs signed rank test (Graph Pad Prism 6). Respective p-values are indicated. N gives the number of analysed patient samples. MFI, mean
fluorescence intensity; ns, not significant.
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Few studies investigated the expression profile of differ-
ent RFs in HIV-1-positive individuals controlling the infec-
tion without therapy and found either no [7], a subset-
specific association [45] or correlation of RF expression
with cellular activation status [5]. The latter study, which
analysed 42 HIV-1 RFs by mRNA profiling, found enhanced
expression of Schlafen11 in CD4+ T cells from elite control-
lers, whereas there were no differences between control-
lers and uninfected individuals.
Herein, we comprehensively profiled RF transcriptional
levels and relative protein expression in a cohort of ther-
apy-naïve HIV-1 controllers as well as individuals progres-
sing to disease. By this, we challenged the hypothesis that
levels of RFs investigated here (SAMHD1, p21, RISP,
Tetherin) could influence the pathogenic course of HIV-1
infection and might contribute to HIV-1 control in vivo. We
report no differences in RF expression in total PBMC of HIV-
1 controllers versus progressors (Figures 1 and 2), but CD4
levels were lower in progressors as expected [32], indepen-
dently confirming the validity of our cohort analyses.
Interestingly, when we included the proposed HIV-1
latency marker CD2 [31], there was a clear and robust
association of high HIV-1 RF expression levels with the
expression of CD2 across all patients (Figure 4). In line,
HIV-1 p24 was increased in PBMC, CD3+ and CD4+ cells
with low CD2 levels (Figure 5). From this data, it is tempting
to postulate an overall important role of the analysed RFs
for cell-associated HIV-1 p24 levels, i.e. viral gene expres-
sion. While such a conclusion would be in line with the
biological function of RFs and the growing body of in vitro
results [1,3], it has to be postulated very cautiously. First, as
it is the case for most clinical studies, we report correla-
tions, no causalities. Second, our results could also simply
reflect higher activation of HIV-1-positive cells, which would
lead to increased p24 and lower RF expression. While such
a scenario has to be considered, our experimental evidence
and the literature do not support this. Cell surface CD2 is
associated with T cell activation and increased post TCR
stimulation of primary naïve CD4+ T cells [35,46] and PBMC
(Figure S3). Furthermore, we measured additional markers
on the surface of CD2+ versus CD2low cells (Figure S4) which
remained either unchanged between both groups (CD132
and CD134) or were significantly reduced (CD229) on
CD2low cells. CD132 and CD134 are cytokine/chemokine
receptors and CD229 is a SLAM family member involved
in T cell activation. All these receptors are upregulated
Figure 5. Levels of HIV-1 p24 antigen in CD2+ versus CD2low cells of HIV-1-positive individuals. (a) Intracellular p24 in CD2+ vs. CD2low
cells. Intracellular p24 in (b) CD2+ cells from HIV-1 controllers versus progressors and (c) in CD2low cells of HIV-1 controllers versus
progressors. The values in a–c were further specifically analysed for CD2 and p24 expression in the whole PBMC population (panel 1), the
CD3+ fraction (panel 2) and the CD4+ fraction of cells (panel 3). Each data point represents the specific flow cytometry measured
percentage of p24+ cells in the CD2+ or CD2low population. Values were plotted and assessed for statistical significance using an unpaired
two-tailed Mann–Whitney test assuming non-Gaussian distribution (Graph Pad Prism 6). N = 44 (compare Table 1). Specific p-values are
indicated above each subpanel. ns, not significant.
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upon canonical TCR stimulation of naïve T cells [35],
strongly indicating that the low RF expression levels of the
CD2low T cell population are not a consequence of cellular
activation. We also tried to recapitulate the phenotype in
ex vivo TCR stimulated and experimentally HIV-1-positive
CD4+ T cells from healthy individuals and measured CD2 as
well as RFs and p24 levels (data not shown). However
unfortunately, CD2 levels rapidly and dramatically changed
as soon as PBMC or CD4+ T cells were cultured ex vivo,
precluding the analyses of a potential association between
CD2 expression and infection in cell culture experiments.
We herein detected robust p24 levels in the PBMC popu-
lation of HIV-1-positive individuals, when using the well-
established p24 KC57 clone from Beckman-Coulter. In a
recent study, the authors also used this clone to detect
p24 in patient samples [33]. In agreement to the results
of Baxter and colleagues, we found that this antibody
generated some background signal in patient PBMC which
was in our hands in the range of ~0.1% of cells. This is quite
high given that some of our patient samples had p24 levels
of 0.13%, which is close to background. On the other hand,
the measured p24 levels in our cohort of therapy naïve
controllers and progressors were higher throughout than in
our controls, i.e. three healthy donors and three patients
on ART (Figure 2(c) and Figure S5). In conclusion, although
the KC57 p24 antibody generates some background, the
reagent allows to measure a specific p24 signal. In agree-
ment, when we gated on CD3+ or CD4+ cells (Figure 5 and
Figure S5), the amount of p24+ cells constantly increased,
as expected when specifically deconvoluting for HIV-1 tar-
get cells. Furthermore, CD2low CD4+ cells from progressing
individuals harboured significantly more p24 than those of
controllers and viral loads directly correlated with p24
levels in the CD2low CD4+ T cells (Figure 5(c) panel 3 and
Figure 6(a)). This indicates that the extent of CD2low CD4+ T
cell infection might be linked to the course of HIV-1 infec-
tion and viral loads in patients.
Overall, we identify here in PBMC isolated from therapy
naïve HIV-1-positive individuals a positive correlation
between CD2 and the expression of selected host RFs,
mainly p21 and SAMHD1. This phenotype inversely corre-
lates with cell-associated HIV-1 p24 antigen and supports
an important role of RFs in vivo.
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